All News

Found 16,632 articles

• The Day In Review: Does Tamiflu Cause Serious Side Effects?

  11/17/2005

• Labopharm's Once-Daily Tramadol Product Launched In Germany

  11/17/2005

• Myogen Files Shelf Registration Statement

  11/17/2005

• Speedel Pharmaceuticals, Inc. Release: Aliskiren, The First Effective Oral Renin Inhibitor, Provides Sustained 24 Hour Blood Pressure Control In Combination With Angiotensin Receptor Blocker

  11/16/2005

• Novartis Pharmaceuticals Corporation Release: NAVIGATOR Data Presented At American Heart Association's Scientific Sessions Provide New Insights About Cardiovascular And Diabetes Risk

  11/16/2005

• Speedel Pharmaceuticals, Inc. Announces Financial Results For First Nine Months 2005

  11/16/2005

• Novartis Corporation Transplant Drug Study Lacking

  11/15/2005

• FDA Rebuffs Novartis Pharma AG Over Delay To Biogeneric Drug

  11/15/2005

• Anadys Pharmaceuticals, Inc. To Be Added To The NASDAQ Biotechnology Index (NBI)

  11/15/2005

• Idenix Pharmaceuticals, Inc. Release: GLOBE Study Demonstrates Telbivudine Provides Significantly Greater Response On Antiviral Measures Vs. Lamivudine In Patients With Chronic Hepatitis B, The 10th Leading Cause Of Death Worldwide

  11/14/2005

• Speedel Group Release: SPP301 Phase IIb Results In Diabetic Nephropathy Presented At ASN

  11/14/2005

• Anadys Pharmaceuticals, Inc. Release: ANA975 Phase I Clinical Data To Be Presented At The American Association for Study of Liver Diseases Annual Meeting

  11/14/2005

• Novartis Pharmaceuticals Corporation Release: GLOBE Study Demonstrates Telbivudine Provides Significantly Greater Response On Antiviral Measures Vs. Lamivudine In Patients With Chronic Hepatitis B, The 10th Leading Cause Of Death Worldwide

  11/14/2005

• Inyx, Inc.'s Ashton Pharmaceuticals Launches Production On An Asthma Dry Powder Inhaler For Mercator Genetics, A Unit Of Merck KGaA

  11/14/2005

• Idenix Pharmaceuticals, Inc. Release: Valopicitabine (NM283) Combined With Pegylated Interferon Demonstrated Significantly Greater Suppression Of Hepatitis C Virus (HCV) Replication In Treatment-Refractory Patients Compared To Retreatment With Ribavirin P

  11/11/2005

• Myogen Announces Achievement Of Target Enrollment For Pivotal Phase 3 ARIES-1 Trial Of Ambrisentan In PAH

  11/11/2005

• Anadys Pharmaceuticals, Inc. To Present At Credit Suisse First Boston Annual Healthcare Conference

  11/11/2005

• PTC Therapeutics, Inc. Raises $26.6 Million In Private Placement Financing

  11/10/2005

• Emisphere Technologies, Inc. Provides 2005 Third Quarter Update

  11/10/2005

• Avalon Pharmaceuticals Reports Third Quarter 2005 Results

  11/9/2005